Reference : Paget's Disease of Bone Treated with a Five Day Course of Oral Tiludronate
Scientific journals : Article
Human health sciences : Rheumatology
http://hdl.handle.net/2268/57770
Paget's Disease of Bone Treated with a Five Day Course of Oral Tiludronate
English
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Lecart, Marie-Paule mailto [Université de Liège - ULg > > Rhumatologie >]
Deroisy, Rita mailto [Centre Hospitalier Universitaire de Liège - CHU > > Médecine de l'appareil locomoteur >]
Ethgen, Dominique [Université de Liège - ULg > > Epidémiologie et santé publique >]
Zegels, Brigitte [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique]
Franchimont, P. [> > > >]
Jan-1993
Annals of the Rheumatic Diseases
52
1
54-7
Yes (verified by ORBi)
International
0003-4967
[en] Chloro-4-phenyl thiomethylene bisphosphonate (tiludronate) is a new drug which can be used as an inhibitor of bone resorption. As it remains in bone for a long time, and as mineralisation defects have only been seen at doses much higher than those required to decrease osteoclastic activity, it could be given at high doses over a short period of time. Eighteen patients with Paget's disease of bone were randomly allocated to three therapeutic groups receiving respectively 600, 800, and 1200 mg/day tiludronate for five days. Serum alkaline phosphatase activity and the urinary hydroxyproline/creatinine ratio were quickly and drastically reduced in all three groups. A significant reduction of serum alkaline phosphatases and the hydroxyproline/creatinine ratio was still present six months after the five day therapeutic course, reflecting a sustained activity of tiludronate even after stopping treatment. Dose dependent short and long term reductions of bone turnover rate were observed. Biochemical assessment of haematological, renal, or hepatic tolerance did not show any toxicity of tiludronate. Fifty per cent of patients treated by a dose of 1200 mg/day reported gastrointestinal disturbances, however, making this dosage unsuitable for clinical practice.
http://hdl.handle.net/2268/57770

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Paget's Disease of Bone Treated with a Five Day Course of Oral Tiludronate.pdfPublisher postprint703.3 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.